TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: PCL-5 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Manual Ability Measure-36
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disability of Arm Shoulder and Hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bleeding on brushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Experiencing Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Reduction From Baseline in Actinic Keratosis (AK) Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in fasting glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood sugar range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Intraoperative signs of inadequate anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative recall of events
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MLAEP parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard deviation of trunk sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who have undergone health screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Active range of motion (AROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Motor Activity Log 30 (MAL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: F/M ratio of ulnar nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nutritional adequacy during the ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall family satisfaction with ICU
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Teeth healed or healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Improvement Rate in Dry Mouth Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Severity and Frequency of TEAEs - Mild Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Severity and Frequency of TEAEs - Moderate Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Severity and Frequency of TEAEs - Severe Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Performing Self-Testing Two Times per Week Using the Mobile Medical Application
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Visiting their Ophthalmologist at Least Every 8 Weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Degree of Correlation Between mVT Test Results and Certified ETDRS Protocol Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Peak Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Plasma Clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetic parameters of atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-telopeptide (CTX) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowest mean fluence inducing visible pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: International Normalized Ratio (INR) Time in Therapeutic Range (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of orally absorbed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline on Visual Analogue Scale for Drug Liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sound quality benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and Specificity of the Exact CRC diagnostic screening test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Global Health - PROMIS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Health Risk Behavior Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exosome cargo levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in trunk control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atazanavir pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic COVID-19 by 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Severe COVID-19 incidence over 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Shoulder Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant-Murley Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The Disabilities of the Arm, Shoulder and Hand (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: rate of refracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Perception of taste
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of smell
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weighted Average Change From Baseline in Uncorrected Near Visual Acuity (UNVA) Letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Platelet Reactivity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Flow limiting stenosis in the coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of relapse free patients
Endpoint domain: Mortality/survival
Primary endpoint: Absolute change in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in growth parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset date of inadequate oral nutrition, hydration, and/or ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Clinically Significant Exacerbations of Asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cardiac Anxiety Questionnaire (CAQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Body Sensations Questionnaire (BSQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-perceived Lung Cancer Screening Decision Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immediately Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NYHA class evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart-failure-related hospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quality of Life evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression to higher level lesion
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability of Intervention to Patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Female Participants With Positive PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Residual cancer burden (RCB)-0 + RCB-I responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Volume of the most affected leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Localized Scleroderma Cutaneous Assessment Tool - LOSCAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Regional Standardized Uptake Value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional Standardized Uptake Value Ratios (SUVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in SUV for Different Brain Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in SUVR for Different Brain Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Epidural Catheter Migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: The Functional Reach Test (FR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength (MS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Pain Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Curve (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half Life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Plasma Clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Distribution (Vz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Vision Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Referral for ICD Assessment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of overall MS impact in patients life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognition in MS
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fatigue in MS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: time to first biopsy proven acute rejection episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Analog Sleep Scale (VASS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Quality of Recovery Scale (QoR-40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 30 day reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: additional drain placement
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary static hyperinflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage of lumbar BMD modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Discrimination of benign from malignant nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in level of light physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ICD shocks due to VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in amyloid load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of glycaemic disorders (prevalence of diabetes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in manual dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of contrast induced acute kidney injury (CI-AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Subjects Reporting Clinically Significant Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of lung deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in Glutamate Levels (mmol/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neural Reactivity (BOLD response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Primary Open-Angle Glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Improvement of histologic grade of hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Bowel necrosis length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients that died between 30 postsurgical days
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants remaining on PRO 140 monotherapy without virologic failure
Endpoint domain: Mortality/survival
Primary endpoint: serum lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Difference in Change From Baseline in ddQTcF Following a Single Dose of 33 mg/kg Deferiprone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Difference in Change From Baseline in ddQTcF Following a Single Dose of 50 mg/kg Deferiprone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Postdose QT/QTc Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Change From Baseline (dQT/dQTc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients Achieving LDL-C < 100 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline breast milk iodine concentration (µg/L) at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline urinary iodine concentration (µg/L) at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline Infants' anthropometric measurement (Z-score) at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoxic fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of positive SARC-F questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at Day 100
Endpoint domain: Mortality/survival
Primary endpoint: New infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence and change of pain from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence and change of Itching from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating high sensitive C-reactive protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating triacylglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Scores With Cough on First Postoperative Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores With Cough on the Second Postoperative Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU related discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of Pain Measured by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birmingham IBS Symptom Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in gut microbiome as assessed through analyzing fecal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure to control acute bleeding or prevent variceal rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICP mean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICP area under curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3+ rectal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen Saturation change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with positive molecular or serologic testing for SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants with grade 3 or more adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of the prolapse surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pulmonary Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glittre ADL test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: arterial oxygen partial pressure / fractional inspired oxygen ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hb level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients who stop treatment due to CTCAE grade 3 or above toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with low-value utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Undetectable HCV RNA at SVR12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CAPS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Timeline Follow Back (TLFB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of sub-cutaneous antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Oxidized Low-Density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to First Severe Asthma Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence Rate of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Study discontinuation due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Desaturation SPO2 index >10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AHI >5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in star cancellation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in Ogden Figure test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: changes in line bissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: visuo-spatial pointing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: proprioceptive pointing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Recording of adverse events related to VISIA
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Balance-Related Diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Unique Visits With and Without Balance-Related Referrals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Providers' Perceptions Reported as Number of Responses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Genotype-phenotype correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival and mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with HbA1c < 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to achieve afebrile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological complete response (pCR) at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Non-transfusion Dependent Participants With a Hemoglobin Increase of ≥1.5 g/dL From Baseline for ≥14 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes